Short answer: MariTide (maridebart cafraglutide) is Amgen's investigational obesity compound - a long-acting peptide-antibody conjugate that pairs GLP-1 receptor agonism with GIP receptor antagonism and is studied on a once-monthly schedule. Phase 2 data reported weight reductions of up to roughly 20%, with the curve still trending down at 52 weeks; it is now moving into Phase 3. It is investigational, not approved, and supplied here research use only.
Maridebart cafraglutide - trial name MariTide - is one of the most closely watched names in the next wave of obesity research because it does two things differently from the weekly GLP-1 drugs researchers already know. This profile explains what the molecule is, why its mechanism is unusual, and where it sits in the development pipeline.
Plain-English summary. MariTide is a research-stage molecule, not a medicine you can buy or use. Everything below describes published preclinical and clinical-trial findings for laboratory and educational context. New-U supplies research-use-only material and does not provide dosing, medical, or human-use guidance.
MariTide is a long-acting peptide-antibody conjugate developed by Amgen for the investigational treatment of obesity. Conjugating the peptide to an antibody scaffold extends its half-life dramatically, which is what enables the once-monthly dosing interval studied in trials.
The headline feature is that MariTide activates the GLP-1 receptor while blocking the GIP receptor - GIP antagonism, not agonism. That is the opposite of tirzepatide's GIP-agonist arm, and it makes MariTide a live test of competing theories about how GIP signalling influences body weight.
Most GLP-1-class compounds in research are dosed weekly. MariTide's conjugate format has been studied at a once-monthly interval, a potential adherence and access differentiator that is a major reason for the attention it receives.
In a Phase 2 trial published in 2026, MariTide produced mean weight reductions of up to approximately 20% in participants with obesity (and up to roughly 17% in those who also had type 2 diabetes), with weight still declining at 52 weeks rather than plateauing.
MariTide sits in a crowded field of multi-receptor obesity compounds. Tirzepatide is a GLP-1/GIP dual agonist; retatrutide is a GLP-1/GIP/glucagon triple agonist; MariTide takes the GIP-antagonist route on a monthly schedule - three different bets on the same biology.
MariTide has advanced from positive Phase 2 results into Phase 3 development. Approval timelines for an investigational obesity compound at this stage typically run multiple years, subject to trial outcomes and regulatory review.
What is MariTide (maridebart cafraglutide)?
Amgen's investigational once-monthly peptide-antibody conjugate combining GLP-1 agonism with GIP antagonism. Investigational, not approved; research use only.
How is its mechanism different from tirzepatide?
Tirzepatide activates both GLP-1 and GIP receptors; MariTide activates GLP-1 but antagonises GIP - the opposite GIP direction.
Is MariTide once-monthly?
It has been studied on a once-monthly schedule, enabled by its long-acting conjugate format - longer than the weekly GLP-1 agonists.
Is MariTide FDA approved?
No - it is investigational and in clinical development. Material supplied as maridebart cafraglutide is research use only, not for human consumption.
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Browse the catalog